BioWorld

March 19, 2009

View Archived Issues

Medivation Cleared to Begin Pivotal Prostate Cancer Trial

Well under way with pivotal trials of Alzheimer's disease drug Dimebon, Medivation Inc. is moving into late-stage development with another product, MDV3100, an androgen receptor antagonist, in prostate cancer. (BioWorld Today) Read More

Battling FOB Bills Start March Through the House

Read More

Cost Cutting Continues: Cerus Latest Biotech to Slash Jobs

Read More

NewCo News: Auspex Focuses on Metabolism to Get More Bang from Drugs

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More